Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
-
Published:2022-08-30
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Isobe TomoyaORCID, Takagi MasatoshiORCID, Sato-Otsubo Aiko, Nishimura AkiraORCID, Nagae GentaORCID, Yamagishi Chika, Tamura Moe, Tanaka YosukeORCID, Asada ShuheiORCID, Takeda ReinaORCID, Tsuchiya Akiho, Wang Xiaonan, Yoshida KenichiORCID, Nannya Yasuhito, Ueno HirooORCID, Akazawa RyoORCID, Kato ItaruORCID, Mikami TakashiORCID, Watanabe Kentaro, Sekiguchi MasahiroORCID, Seki MasafumiORCID, Kimura Shunsuke, Hiwatari Mitsuteru, Kato Motohiro, Fukuda ShiroORCID, Tatsuno KenjiORCID, Tsutsumi Shuichi, Kanai AkinoriORCID, Inaba Toshiya, Shiozawa YusukeORCID, Shiraishi Yuichi, Chiba Kenichi, Tanaka HirokoORCID, Kotecha Rishi S.ORCID, Cruickshank Mark N.ORCID, Ishikawa FumihikoORCID, Morio TomohiroORCID, Eguchi MarikoORCID, Deguchi TakaoORCID, Kiyokawa NobutakaORCID, Arakawa Yuki, Koh Katsuyoshi, Aoki Yuki, Ishihara TakashiORCID, Tomizawa DaisukeORCID, Miyamura TakakoORCID, Ishii Eiichi, Mizutani Shuki, Wilson Nicola K.ORCID, Göttgens BertholdORCID, Miyano Satoru, Kitamura ToshioORCID, Goyama SusumuORCID, Yokoyama Akihiko, Aburatani HiroyukiORCID, Ogawa SeishiORCID, Takita JunkoORCID
Abstract
AbstractKMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearranged leukemia. Our multi-omics clustering followed by single-sample and single-cell inference of hematopoietic differentiation establishes five robust integrative clusters (ICs) with different master transcription factors, fusion partners and corresponding stages of B-lymphopoietic and early hemato-endothelial development: IRX-type differentiated (IC1), IRX-type undifferentiated (IC2), HOXA-type MLLT1 (IC3), HOXA-type MLLT3 (IC4), and HOXA-type AFF1 (IC5). Importantly, our deep mutational analysis reveals that the number of RAS pathway mutations predicts prognosis and that the most refractory subgroup of IC2 possesses 100% frequency and the heaviest burden of RAS pathway mutations. Our findings highlight the previously under-appreciated intra- and inter-patient heterogeneity of KMT2A-rearranged infant ALL and provide a rationale for the future development of genomics-guided risk stratification and individualized therapy.
Funder
Japan Foundation for Pediatric Research Funai Foundation for Information Technology Japan Agency for Medical Research and Development MEXT | Japan Society for the Promotion of Science MEXT | RIKEN Princess Takamatsu Cancer Research Fund
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference64 articles.
1. Downing, J. R. et al. The pediatric cancer genome project. Nat. Genet. 44, 619–622 (2012). 2. Hilden, J. M. et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 108, 441–451 (2006). 3. Pieters, R. et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an International Phase III Randomized Study. J. Clin. Oncol. 37, 2246–2256 (2019). 4. Tomizawa, D. et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood 136, 1813–1823 (2020). 5. Brown, P. A. et al. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631. Leukemia 35, 1279–1290 (2021).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|